Pharmaceuticals company Morepen Laboratories announced Q2FY25 results Financial Highlights: Net Revenue: Rs 425.00 crore compared to Rs 442.71 crore during Q2FY24, change 4%. EBITDA: Rs 36.83 crore compared to Rs 49.06 crore during Q2FY24, change 33%. EBITDA margin: 8.66% for Q2FY25. PBT: Rs 28.68 crore compared to Rs 46.02 crore during Q2FY24, change 60%. PAT: Rs 21.26 crore compared to Rs 34.85 crore during Q2FY24, change 64%. PAT margin: 5% for Q2FY25. Earnings Per Share: Rs 0.42 for Q2FY25. Sushil Suri, Chairman and Managing Director, Morepen Laboratories, said: “At Morepen, we are all supercharged to execute our strategic mission, ‘Morepen 2.0,’ as we target Rs 5000 crore (5K) in revenue by 2030. We are dedicated to building on our strengths across both domestic and global markets. As we pivot our forthcoming investments towards Medical Devices and Consumer Health, we remain committed to innovation and research in our core API business. We will continue to invest in technology and improve our operational efficiencies. The company continues to remain debt free and we will leverage our cash position to improve our product pipeline.” “We are extremely confident of our growth strategies for achieving our long-term strategic goals. Our Focus remains on developing innovative products, tap newer markets including exports and improve profitability further. With our recent fundraise via the QIP route placing us at the forefront of marquee investors, we are actively evaluating various options to fund our growth plans on our journey to the 5K milestone.“ Result PDF
Pharmaceuticals company Morepen Laboratories announced Q1FY25 results: Net Revenue: Rs 458.64 crore (14% growth YoY) Expenditure: Rs 403.59 crore (8% growth YoY) EBIDTA: Rs 55.05 crore (93% growth YoY) Cash Surplus: Rs 53.89 crore (91% growth YoY) Profit Before Tax (PBT): Rs 48.17 crore (135% growth YoY) Profit After Tax (PAT): Rs 36.17 crore (147% growth YoY) Quarterly EPS: Rs 0.71 (147% growth YoY) The company has successfully completed the subscription of a QIP for Rs 200 crore on August 5, 2024. Sushil Suri, Chairman and Managing Director of Morepen Laboratories, commented on the QIP, stating, “This strategic fundraise marks a pivotal point in the company’s growth journey. With the influx of this new capital, we will accelerate our capacity expansion plans and broaden our market reach.” He further added, “With this fresh infusion of capital, the company can clearly focus on its two growth engines – Medical Devices & Pharma – and reposition itself for growth in select categories with an endto-end supply chain from manufacturing to marketing. We will have an increased focus on research and backward integration, fostering innovation and cost reduction, thereby positioning the company as a reliable partner for global outsourcing in both the Medical Devices and Pharma sectors for export markets.” Suri, commenting on the quarterly performance, added, “We at Morepen, and India as country, are at the inflection point of an expanding Medical Devices market unfolding with a new vision for India to become the manufacturing hub for Medical Devices. The Indian Medical Devices market is estimated to grow 4.5 times to USD 50 billion by 2030 from the current size of USD 11 billion, and is expected to reach USD 250 billion by 2047, as per Invest India estimates. We are preparing ourselves to gain a major market share in the point of care medical devices sector.” Result PDF